viewZelira Therapeutics Ltd

Zelda Therapeutics in trading halt ahead of transaction with US healthcare group

The company’s securities will remain in a trading halt until the beginning of trade on October 10 or when an announcement is released.

Zelda Therapeutics Ltd - Zelda Therapeutics in trading halt ahead of a transaction with US healthcare group
Zelda is a medicinal cannabis company focused on first-in-class human clinical trials for insomnia, autism and opioid reduction

Zelda Therapeutics Ltd (ASX:ZLD) has been granted a trading halt by the ASX ahead of a material control transaction with a US-based healthcare group.

The trading halt will remain in place until the start of normal trading on Thursday, October 10, or when an announcement is made to the market, whichever occurs earliest.

Zelda's shares last traded at 7.8 cents up from 4 cents at the start of the financial year with a new 12-month high of 9.2 cents reached on July 29.

Autism treatment cannabis study

The company marked a major milestone in August after enrolling its 103rd patient in the behavioural study evaluating medicinal cannabis treatment in children on the autism spectrum.

Children are aged about 10-years-old, diagnosed with autism and range in autism levels from classifications of low to medium or high severity.

The study is being undertaken at the Children’s Hospital of Philadalphia (CHOP) where a number of cannabis treatments are being trialled.

Quick facts: Zelira Therapeutics Ltd

Price: 0.032 AUD

Market: ASX
Market Cap: $30.92 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...



Full interview: Zelira Therapeutics releases interim data for Phase II...

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins, chairman Osagie Imasogie and clinical trial principal investigator Professor Peter Eastwood, of the University of Western Australia, update Proactive on results from the company’s Phase II clinical trial of medicinal...

on 21/2/20

2 min read